HIV and AIDS Trial, Recruiting NCT07125235 Sponsor: University of California, San Francisco Condition: HIV and AIDS
Back to Hiv Aids

HIV and AIDS Trial, Recruiting

NCT07125235
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been prescribed HIV treatment (antiretroviral therapy) that includes a medication called tenofovir.
  • People who have either shown signs that their HIV is not fully under control, had a urine test that showed no tenofovir was detected, or reported that they do not take all of their medication doses as prescribed.
  • People who report using stimulant drugs (such as methamphetamine or cocaine).
  • People who have a mailing address within the United States.
  • People who currently own a smartphone that can take photos.

Who may not be able to join:

  • People with a serious health condition that could affect their ability to take part in the study or to give informed consent, including any condition that is severely disabling or life-threatening.
  • People who have not been prescribed HIV treatment (antiretroviral therapy).
  • People who are not willing to do urine self-testing at home or to visit a local Quest Diagnostics site for viral load monitoring.
  • People who are unable to provide a hair sample of roughly 50–100 strands of hair that is not gray, not bleached, and at least 1 cm (about half an inch) long.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Matthew Spinelli, MD, MAS, University of California, San Francisco

Phone: 415-878-6384

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
9 February 2026
Est. completion
30 April 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Viral suppression measured by HIV-1 RNA, Quantitative, Real-Time PCR

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov